Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mirati Therapeutics, Inc.    MRTX

MIRATI THERAPEUTICS, INC.

(MRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
223.41(c) 225.46(c) 232.54(c) 237.85(c) 234.36(c) Last
363 580 283 843 202 849 618 586 411 129 Volume
-0.71% +0.92% +3.14% +2.28% -1.47% Change
More quotes
Financials (USD)
Sales 2020 12,0 M - -
Net income 2020 -367 M - -
Net cash position 2020 986 M - -
P/E ratio 2020 -29,0x
Yield 2020 -
Sales 2021 14,7 M - -
Net income 2021 -414 M - -
Net cash position 2021 870 M - -
P/E ratio 2021 -28,2x
Yield 2021 -
Capitalization 11 959 M 11 959 M -
EV / Sales 2020 915x
EV / Sales 2021 755x
Nbr of Employees -
Free-Float 91,3%
More Financials
Company
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS... 
Sector
Biotechnology & Medical Research
Calendar
12/01 | 05:20pmPräsentation
More about the company
Notations Surperformance© of Mirati Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MIRATI THERAPEUTICS, INC.
11/24MIRATI THERAPEUTICS : to Participate In the 2020 Evercore ISI HealthCONx Confere..
AQ
11/04MIRATI : 3Q Earnings Snapshot
AQ
11/04MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
11/02MIRATI THERAPEUTICS : Announces Closing of Public Offering of Common Stock and F..
AQ
10/28MIRATI THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
10/28MIRATI THERAPEUTICS : Announces Pricing of Public Offering of Common Stock
AQ
10/27MIRATI THERAPEUTICS : Announces Proposed Public Offering of Common Stock
AQ
10/26MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition (form ..
AQ
10/26MIRATI THERAPEUTICS : Reports Investigational Adagrasib Preliminary Data Demonst..
AQ
10/26MIRATI THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial St..
AQ
10/16MIRATI THERAPEUTICS : to Present Data during the 2020 EORTC-NCI-AACR Internation..
AQ
10/14INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
10/06INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
09/20MIRATI THERAPEUTICS : Amgen drug shrinks tumors in lung cancer patients with KRA..
RE
09/18MIRATI THERAPEUTICS : Boehringer Ingelheim And Mirati Therapeutics Announce Clin..
AQ
More news
News in other languages on MIRATI THERAPEUTICS, INC.

- No features available -

More news
Chart MIRATI THERAPEUTICS, INC.
Duration : Period :
Mirati Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRATI THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 230,62 $
Last Close Price 237,85 $
Spread / Highest target 11,4%
Spread / Average Target -3,04%
Spread / Lowest Target -26,0%
EPS Revisions
Managers
NameTitle
Charles M. Baum President, Chief Executive Officer & Director
Faheem Hasnain Chairman
Daniel R. Faga Executive VP, Chief Operating & Financial Officer
James G. Christensen Chief Scientific Officer & Executive VP
Philip Roberts Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MIRATI THERAPEUTICS, INC.84.58%11 959
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE266.71%29 915